Barriers to and Motivations for the Implementation of a Treatment Programme for Latent Tuberculosis Infection Using Isoniazid for People Living With HIV, in Upper Northern Thailand

Global journal of health science - Canada
doi 10.5539/gjhs.v5n4p60
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Canadian Center of Science and Education

Related search

Implementation of Co-Trimoxazole Prophylaxis and Isoniazid Preventive Therapy for People Living With HIV

Bulletin of the World Health Organization
EnvironmentalPublic HealthOccupational Health
2009English

Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

Medication Beliefs and Structural Barriers to Treatment Adherence Among People Living With HIV Infection

Psychology and Health
EnvironmentalPublic HealthApplied PsychologyOccupational Health
2015English

Optimizing Implementation of Universal HIV Treatment Coverage for People Living With HIV in Senegal

2018English

Point-Of-Care C-Reactive Protein Testing to Facilitate Implementation of Isoniazid Preventive Therapy for People Living With HIV

Journal of Acquired Immune Deficiency Syndromes
Infectious DiseasesPharmacology
2014English

Tuberculosis Infection and Disease in People Living With HIV in Countries With Low Tuberculosis Incidence

International Journal of Tuberculosis and Lung Disease
MedicinePulmonaryInfectious DiseasesRespiratory Medicine
2018English

The Impact of Smoking on Adherence to Treatment for Latent Tuberculosis Infection

BMC Public Health
EnvironmentalPublic HealthOccupational Health
2006English

The Economic Burden of Tuberculosis and Latent Tuberculosis in People Living With HIV in Brazil: A Cost Study From the Patient Perspective

Public Health
MedicineEnvironmentalPublic HealthOccupational Health
2018English

Treatment Completion for Latent Tuberculosis Infection: A Retrospective Cohort Study Comparing 9 Months of Isoniazid, 4 Months of Rifampin and 3 Months of Isoniazid and Rifapentine

BMC Infectious Diseases
Infectious Diseases
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy